What the Lawsuits Allege
The litigation targets Gilead Sciences over HIV medications built on tenofovir disoproxil fumarate, or TDF, including Truvada along with Viread, Atripla, Complera, and Stribild. Plaintiffs allege that TDF is toxic to the kidneys and bones, causing kidney disease or failure and bone density loss or fractures, and that Gilead failed to warn patients and doctors adequately about these risks.
A central and distinctive allegation is that Gilead had developed a safer version of the drug, based on a compound called TAF, but deliberately delayed bringing it to market for years to maximize revenue from the patent-protected TDF drugs. Gilead disputes the claims. It has stated that resolving cases is not an admission of liability or wrongdoing, and the drugs have not been recalled and remain on the market.
Two Tracks: Federal and California
The litigation runs on two tracks. In federal court, Gilead reached an agreement in principle, reported around 2024, to pay roughly 40 million dollars to resolve about 2,625 cases involving kidney and bone injuries, subject to a high opt-in threshold among claimants. That federal resolution is modest in per-person terms and does not cover the much larger body of state cases.
The far larger track is in California state court, where tens of thousands of cases, reported above twenty thousand, are consolidated before a single judge. Bellwether trials have been moving forward there to test how juries respond.
The Pivotal California Ruling
The center of gravity in this litigation is a landmark question before the California Supreme Court, expected to be decided in 2026, concerning whether a manufacturer can be held liable for failing to bring a safer drug to market sooner. That novel theory is what makes these cases unusual, and the court answer could significantly raise or lower their value.
Until that decision and the bellwether results come in, there is no reliable figure for what an individual case is worth, and the verified federal deal is not a predictor of state outcomes. Eligibility generally centers on having taken a TDF-based Gilead drug and suffered kidney or bone injury, and because deadlines apply, an individual assessment is the right step.
How to Get Legal Help
If you or a family member fits the description here, a consultation with a lawyer who handles this specific litigation is the reliable next step. Deadlines vary and can be unforgiving, most of these firms offer a free review, and these cases are typically taken on contingency, so you pay nothing unless they recover for you.
To follow filings, trial outcomes, and any settlement news, bookmark this page and subscribe to LawsuitWatch alerts.
Free Legal Evaluation
Do You Qualify to File a Claim?
Our network of verified plaintiff attorneys offers free, no-obligation case evaluations. Contingency fee representation means you pay nothing unless you win.
Truvada Lawsuit Update: The TDF Kidney and Bone Cases: Frequently Asked Questions
Answers to the most common questions about this case and your legal options.
What do the Truvada lawsuits allege?
That Gilead TDF-based HIV drugs, including Truvada, Viread, Atripla, Complera, and Stribild, are toxic to the kidneys and bones and that Gilead failed to warn adequately, and that Gilead delayed a safer version, TAF, to maximize TDF revenue. Gilead disputes the claims.
Is Truvada recalled?
No. The TDF drugs have not been recalled and remain on the market. The litigation is about alleged failure to warn and the delay of a safer alternative, not a recall.
Is there a Truvada settlement?
In federal court, Gilead reached an agreement in principle, reported around 2024, to pay roughly 40 million dollars to resolve about 2,625 kidney and bone injury cases, subject to a high opt-in threshold. It does not cover the much larger body of California state cases.
Why does the California ruling matter?
A landmark question before the California Supreme Court, expected in 2026, concerns whether a manufacturer can be liable for failing to bring a safer drug to market sooner. That novel theory is central, and the answer could significantly raise or lower case value.
Who may qualify?
Generally someone who took a TDF-based Gilead drug and suffered kidney or bone injury. Until the California ruling and bellwether results, there is no reliable individual figure, and deadlines apply, so a prompt assessment matters.